The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...
The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.
The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
In D’Iberville, those battling Parkinson’s Disease are slipping on the gloves and fighting back thanks to SAAD Healthcare’s Rock Steady Boxing classes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback